[Stabilizing affective symptoms without adverse cardiac effects. Myocardial infarct risk after depression--and vice versa].
作者信息
Deuschle Michael
机构信息
Zentralinstitut für seelische Gesundheit, J 5, D-68159 Mannheim.
出版信息
MMW Fortschr Med. 2002 May 30;144(22):54-5.
PMID:12116574
Abstract
摘要
相似文献
1
[Stabilizing affective symptoms without adverse cardiac effects. Myocardial infarct risk after depression--and vice versa].
MMW Fortschr Med. 2002 May 30;144(22):54-5.
2
Depression and panic disorder after heart transplantation--treatment with sertraline.
Pharmacopsychiatry. 2002 Jan;35(1):31-2. doi: 10.1055/s-2002-19835.
3
Predictors of treatment response for depression and inadequate social support--the ENRICHD randomized clinical trial.
Psychother Psychosom. 2008;77(1):27-37. doi: 10.1159/000110057. Epub 2007 Dec 14.
4
Clinical efficacy and safety of the Shugan Jieyu capsule in patients with acute myocardial infarction and depression.
Int J Psychiatry Med. 2016 Aug;51(6):534-543. doi: 10.1177/0091217417696740. Epub 2017 Mar 20.
5
Sertraline for treatment of depression in acute coronary syndromes.
JAMA. 2002 Nov 20;288(19):2403; author reply 2403-4. doi: 10.1001/jama.288.19.2403-jlt1120-1-2.
6
Sertraline for treatment of depression in acute coronary syndromes.
JAMA. 2002 Nov 20;288(19):2403; author reply 2403-4. doi: 10.1001/jama.288.19.2403.
7
Antidepressants may temper heart-disease risk.
Health News. 2003 Oct;9(10):11.
8
[Clinical criteria for choosing an antidepressive drug].
Encephale. 1995 Dec;21 Spec No 4:19-21.
9
Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline.
Compr Psychiatry. 2003 Sep-Oct;44(5):360-9. doi: 10.1016/S0010-440X(03)00111-1.
10
Treatment of postpsychotic depression with sertraline in patients with schizophrenia--own experience.
Neuropsychopharmacol Hung. 2006 Oct;8(3):155-6.
Zotero 插件